Insights Into Bladder Cancer
Perspectives on the current treatment practices of non–muscle-invasive and muscle-invasive bladder cancer. Insights on the management of metastatic urothelial cancer
Faculty Chair(s)
Petros Grivas, MD, PhD
University of Washington, USA
Look Inside This Report
Download a sample of this report and start discovering the insights
Key Takeaways
- Community oncologists noted that the genitourinary oncology field is evolving at a rapid pace, challenging their ability to stay current
- The introduction of checkpoint inhibitors in various stages of bladder cancer therapy is considered the most important recent treatment advance, together with erdafitinib (FGFR2/3 inhibitor) and enfortumab vedotin (antibody-drug conjugate) data
- Physicians believe pembrolizumab is the checkpoint inhibitor with the most robust data overall in bladder cancer
- Clinical trials and biomarkers are needed to determine proper sequencing
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
A moderated roundtable discussion focusing on treatment of bladder cancer
Disease state and data presentations were developed in conjunction with Dr Petros Grivas, a medical expert from the University of Washington
The group of advisors comprised community oncologists from the Southwest
Insights on actual and investigational therapies were obtained in early stage non–muscle- and muscle-invasive disease, as well as advanced metastatic bladder cancer
Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
